Skip to main content

Table 1 Study characteristics

From: Dose approach matter? A meta-analysis of outcomes following transfemoral versus transapical transcatheter aortic valve replacement

Lead author

Ayman Elbadawi [34]

Wilko Reents [33]

Mohammed A. Al-Hijji [26]

Takahide Arai [27]

Edward Koifman [28]

Takashi Murashita [21]

Martine Gilard [30]

Publication year

2020

2019

2019

2016

2016

2016

2016

Journal

Cardiol Ther

EUR J CARDIO-THORAC

Catheter Cardio Inte

JACC-Cardiovasc Inte

Cardiovasc Revasc Med

Ann Thorac Surg

JACC

Study design

Retrospective

Retrospective

Retrospective

Prospective

Retrospective

Retrospective

Prospective

Study period

2011–2014

2009–2016

2012–2016

2011–2014

2007–2014

2008–2015

2010–2012

Procedure

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

Cohort number

2718

2719

619

511

115

115

467

42

516

132

351

216

3064

735

Age, years

78.6 ± 8.5

78.3 ± 8.6

81 (59–95)

81 (67–94)

82.5 ± 7.7

82.8 ± 7.8

83.8 ± 7.1

81.3 ± 7.7

83 ± 8

84 ± 7

79.6 ± 9.7

82.0 ± 7.5

83.2 ± 7.0

81.7 ± 7.5

Male sex

1430(52.6%)

1389(51.1%)

248 (40%)

259 (51%)

60(52.2%)

63(55.3%)

234(50%)

30(71%)

264(51%)

58(44%)

211 (60.1%)

123 (56.9%)

1448(47.3%)

428(58.2%)

STS score,%

N/A

N/A

N/A

N/A

10.0 ± 5.2

10.6 ± 4.7

6.2 ± 3.9

7.1 ± 4.2

8.7 ± 4.5

10.4 ± 4.6

8.8 ± 6.5

9.4 ± 5.4

N/A

N/A

EuroScore,%

N/A

N/A

17 (2–67)

24 (4–79)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

21.2 ± 14.0

23.9 ± 14.8

Diabetes mellitus

453(16.7%)

503(18.5%)

205 (33%)

177 (35%)

44(38.3%)

46(40.4%)

103(22%)

11(26%)

171(35%)

38(30%)

141 (40.2%)

84 (38.9%)

753(24.7%)

192(26.6%)

Chronic renal failure

1129(41.5%)

1098(40.4%)

345 (56%)

281 (59%)

N/A

N/A

N/A

N/A

N/A

N/A

6 (1.7%)

5 (2.3%)

79(2.6%)

18(2.5%)

COPD

1103(40.6%)

1019(37.5%)

80 (13%)

54 (11%)

77(67%)

70(61.4%)

59(13%)

8(19%)

164(33%)

47(37%)

236 (67.2%)

126 (58.3%)

740(24.3%)

158(21.7%)

Atrial fibrillation

N/A

N/A

157 (25%)

139 (27%)

52(45.2%)

48(42.1%)

132(28%)

18(43%)

212(43%)

52(41%)

N/A

N/A

823(27.6%)

160(22.1%)

Previous stroke

N/A

N/A

76 (12%)

69 (14%)

10(8.7%)

14(12.3%)

13(3%)

2(5%)

60(13%)

29(24%)

83 (23.6%)

71 (32.9%)

286(9.4%)

84(11.7%)

Previous infectious endocarditis

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Previous valve surgery

N/A

N/A

2 (0.3%)

8 (1.6%)

N/A

N/A

N/A

N/A

N/A

N/A

90 (25.6%)

44 (20.4%)

50(1.6%)

12(1.7%)

Previous myocardial infarction

390(14.3%)

399(14.7)

68 (11%)

78 (15%)

N/A

N/A

15(3%)

2(5%)

N/A

N/A

100 (28.5%)

80 (37.0%)

439(14.4%)

169(23.4%)

Lead author

Vinod H Thourani [24]

Fausto Biancari [22]

Eugene H. Blackstone [25]

Gerhard Schymik [29]

Martyn Thomas [6]

Craig R. Smith[23]

Johan M. Bosmansa[16]

Publication year

2016

2015

2015

2015

2011

2011

2011

Journal

Lancet

Am J Cardiol

Circulation

Circ-Cardiovasc Int

Circulation

NEJM

Inter Cardiov Th

Study design

Prospective

Prospective

Prospective

Prospective

Retrospective

RCT

Retrospective

Study period

2014.2–2014.9

2010–2012

2007–2012

2008–2012

2007–2009

2007–2009

-2010

Procedure

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

Cohort number

948

126

199

199

501

501

354

354

463

575

492

207

99

88

Age, years

82.1 ± 6.57

80.7 ± 6.69

81.5 ± 6.2

81.2 ± 6.6

218 (44%)

85 ± 6.3

81.7 ± 5.0

81.8 ± 5.9

81.7 ± 6.7

80.7 ± 7.0

84.4 ± 6.7

83.2 ± 6.5

84 ± 5

82 ± 6

Male sex

577(60.9%)

85(67.5%)

111 (55.8%)

104 (52.3%)

283(56%)

272(54%)

164(46.3%)

161(45.4%)

208(44.9%)

254(45.2%)

284 (57.8%)

115 (55.8%)

N/A

N/A

STS score, %

5.3 ± 1.29

5.6 ± 1.28

14.9 ± 11.8

15.0 ± 10.6

N/A

N/A

N/A

N/A

N/A

N/A

11.7 ± 3.3

11.8 ± 3.5

N/A

N/A

EuroScore, %

N/A

N/A

8.1 ± 7.1

8.4 ± 7.3

N/A

N/A

23.5 ± 16.3

23.0 ± 15.6

25.8 ± 14.4

29.1 ± 16.2

29.1 ± 16.1

29.8 ± 15.9

29 ± 15

33 ± 17

Diabetes mellitus

N/A

N/A

52 (26.1%)

50 (25.1%)

184(37%)

185(375)

N/A

N/A

N/A

N/A

N/A

N/A

10(10%)

19(18%)

Chronic renal failure

N/A

N/A

5 (2.5%)

5 (2.5%)

96(195)

92(18)

29(8.2%)

26(7.3%)

118(25.5%)

187(32.5%)

46(9.5%)

16(7.9)

N/A

N/A

COPD

270 (28.5%)

51(40.5%)

44 (22.1%)

50 (25.1%)

221(44%)

214(43%)

46(13%)

47(13.3%)

114(24.6%)

172(29.9%)

211(42.9%)

91(44.0%)

N/A

N/A

Atrial fibrillation

342(36.1%)

43/(34.1%)

N/A

N/A

109(22%)

100(20%)

N/A

N/A

N/A

N/A

106(38.7%)

47(50.5)

N/A

N/A

Previous stroke

81(8.5%)

16(12.7%)

4 (2.0%)

7 (3.5%)

N/A

N/A

N/A

N/A

N/A

N/A

116(25.4%)

66(35.7%)

N/A

N/A

Previous infectious endocarditis

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Previous valve surgery

51(5.4%)

4(3.2%)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Previous myocardial infarction

133 (14.0%)

39 (31.0%)

54 (27.1%)

53 (26.6%)

136(27%)

140(28%)

46(13%)

47(13.3%)

N/A

N/A

128(26.4%)

67(33.2%)

N/A

N/A

Lead author

See Hooi Ewe [17]

Peter Wenaweser [19]

Rafal Dworakowsk [20]

Josep Rodés-Cabau [31]

Martyn Thomas [15]

Helene Eltchaninoff[18]

Nawwar Al-Attar[32]

Publication Year

2011

2011

2011

2010

2010

2010

2009

Journal

Ann Thorac Surg

Am Heart J

Am Heart J

JACC

Circulation

European Heart Journal

Ann Thorac Surg

Study design

Retrospective

Prospective

Prospective

Retrospective

Retrospective

Retrospective

Prospective

Study period

N/A

N/A

2007–2009

2005–2009

2007–2009

2009.2–2009.6

2006–2008

Procedure

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

TF-TAVR

TA-TAVR

Cohort number

45

59

130

27

67

84

162

177

463

575

161

71

35

15

Age, years

82.2 ± 7.1

79.4 ± 8.3

82.9 ± 5.0

83.9 ± 4.0

83 ± 0.8

82.2 ± 0.8

83 ± 8

80 ± 8

81.7 ± 6.7

80.7 ± 7.0

82.3 ± 7.3

82.1 ± 7.3

83 ± 6

83 ± 10

Male sex

21 (46.7%)

31 (52.5%)

50 (23%)

9 (33%)

43 (51%)

39 (58%)

91 (56.1%)

61(34.5%)

208(44.9%)

254(45.2%)

86(53%)

46(64.7%)

18(51.4%)

9(60%)

STS score, %

8.5 ± 3.8

8.9 ± 3.5

N/A

N/A

N/A

N/A

9.0 ± 5.8

10.5 ± 6.9

N/A

N/A

18.9 ± 12.8

18.4 ± 12.1

15 ± 6

19 ± 9

EuroScore, %

20.1 ± 11.7

22.6 ± 11.9

N/A

N/A

19.4 ± 1.1

23.4 ± 1.5

N/A

N/A

25.8 ± 14.4

29.1 ± 16.2

25.6 ± 11.4

26.8 ± 11.6

26 ± 14

30 ± 12

Diabetes mellitus

13 (28.9%)

16 (27.1%)

27 (20.8%)

8 (29.6%)

18 (26.9%)

17 (20.2%)

37 (22.8%)

42(23.7%)

N/A

N/A

46(28.5%)

18(25.3%)

6(17%)

4(27%)

Chronic renal failure

10 (22.2%)

13 (22%)

N/A

N/A

28 (41.8%)

52 (61.9%)

7 (4.3%)

3(1.7%)

118(25.5%)

187(32.5%)

N/A

N/A

9(26%)

8(53%)

COPD

11 (24.4%)

17 (28.8%)

N/A

N/A

15 (22.4%)

26 (31%)

45 (27.8%)

55(31.1%)

114(24.6%)

172(29.9%)

N/A

N/A

10(29%)

4(27%)

Atrial fibrillation

8 (17.8%)

14 (23.7%)

37 (28.5%)

6 (22.2%)

N/A

N/A

66 (40.7%)

49(27.7%)

N/A

N/A

N/A

N/A

N/A

N/A

Previous stroke

2 (4.4%)

10 (17%)

N/A

N/A

N/A

N/A

27 (16.7%)

50(28.2%)

N/A

N/A

16(9.9%)

6(8.4%)

4(11%)

3(20%)

Previous infectious endocarditis

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Previous valve surgery

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Previous myocardial infarction

10 (22.2%)

14 (23.7%)

24 (18.5%)

4 (14.8%)

N/A

N/A

82 (50.6%)

91(51.4%)

N/A

N/A

42(26%)

10(14%)

4(11%)

7(47%)

  1. Data are n (%), or mean ± SD; TF-TAVR = transfemoral transcatheter aortic valve replacement; TA-TAVR = transapical transcatheter aortic valve replacement; COPD = chronic obstructive pulmonary disease; STS = Society of Thoracic Surgeons
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us